Drostanolone Propionate 100

Total Page：16

File Type：pdf, Size：1020Kb

Drostanolone Propionate 100 → SHOP OUR ONLINE STORE ← (Drostanolone Propionate) Drostanolone Propionate is an anabolic androgenic steroid that first hit the market around 1970 under the trade name Masteron manufactured by Syntex. However, the compound was actually developed by Syntex in 1959 along with Oxymetholone (Anadrol) but would not be released until well after Anadrol. #run #running #runner #trailrunning #instarunners #runhappy #runnersofinstagram #instarun #instarunner #runningmotivation #trailrun #runnersworld #trailrunner #runnerslife #runningcommunity #runnerscommunity #runchat #loverunning #runningroom #runclub #runningcoach #runstrong #strengthtraining #runningwomen #womenwhorun #runningmen #menwhorun #fitness #training #workout 640 I don't try and be like, or compete with anyone. You are you and I am me. You all look great . I am only in competition with my own mind and challenge my injuries to stop me progressing. https://blog.libero.it/wp/themaxxri/wp-content/uploads/sites/64365/2020/09/Buy-Steroids-In-Bulgaria-html.pdf https://blog.libero.it/wp/yuliyasergeeva/wp-content/uploads/sites/64427/2020/09/Tri-Trenbolone-200-Magnus-html.pdf Drostanolone propionate, or dromostanolone propionate, sold under the brand names Drolban, Masteril, and Masteron among others, is an androgen and anabolic steroid (AAS) medication which was used to treat breast cancer in women but is now no longer marketed. It is given by injection into muscle.. Side effects of drostanolone propionate include symptoms of masculinization like acne, increased ... #mundoverde_brasil #mundoverdecopacabanaoficial #zonasulrj #produtosnaturais #suplemento #atleta #vegano #vegan #vegetariano #proteinavegana #wheyprotein #essentialnutrition #musculação #ifbb #physique #crossfitbrasil #crossfit #pilates #yoga #corrida #fitness #atividadefisica #treino #nutricaoesportiva #nutricionista #personal #coach #copacabana #rj #hallöchen #GutenTag #bamberg #love #instagood #fashion #photooftheday #followme #likeforlike #daslebengenießen #Beach #musik #machtspaß #fitness #training #sport #sportlife #ifbb #bikini #gym #jogging #bleibfit #bleibgesund #martaaria #seistetsduselbst Drostanolone propionate, or dromostanolone propionate, bought beneath the emblem names Drolban, master. It additionally Masteron among others, is an androgen and anabolic steroid medication. It additionally Masteron among others, is an androgen and anabolic steroid medication. #morning #restday #dietplan #teatime #metabolism #HIIT #eatwellbewell #nutrition #leanmusclegains #cjwingchun #fitnessmotivation #stability #strengthtraining #fitness #fight #sport #workout #gym #healthylifestyle #selfdefense #fittest #muscle #strong #bodybuilding #beastmode #malaysia #athletes #trainhard 1349 Masteron, also known as Drostanolone is a dihydrotestosterone derived androgenic anabolic steroid. It was first introduced for medical use back in the 1960s. As with many steroids, Drostanolone was used to help treat advanced breast cancer. Nowadays, bodybuilders and gym rats use this compound as a performance-enhancing drug..

Copy Link

Recommended publications

A Simple Toxicological Analysis of Anabolic Steroid Preparations from the Black Market
Ann Toxicol Anal. 2012; 24(2): 67-72 Available online at: c Société Française de Toxicologie Analytique 2012 www.ata-journal.org DOI: 10.1051/ata/2012011 Original article / Article original A simple toxicological analysis of anabolic steroid preparations from the black market Analyse toxicologique simple de stéroïdiens anabolisants provenant de marchés parallèles Manuela Pellegrini, Maria Concetta Rotolo, Rita Di Giovannadrea, Roberta Pacifici, Simona Pichini Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Via le Regina Elena 299, 00161 Rome, Italy Abstract – Objectives: A simple and rapid gas chromatography (GC) method with mass spectrometry (MS) detection was developed for the identification and quantification of anabolic steroids in pharmaceutical preparations from the black market. Material and Methods: After a liquid-liquid extraction of pharmaceutical products at acidic, neutral and basic pH with chloroform-isopropanol (9:1, v/v), the different steroids were separated by fused silica capillary column and detected by electron impact (EI)-MS in positive ionization mode. Results and Conclusion: The assay was validated in the range from 10 mg to 250 mg/g powder preparations and 0.02 mg to 200 mg/mL liquid preparations with good determination coefficients (r2 0.99) for the calibration curves. At three concentrations spanning the linear dynamic ranges of the calibration curves, mean recoveries were always higher than 90% and intra-assay and inter-assay precision and accuracy were always better than 15%. This method was successfully applied to the analysis of 15 pharmaceutical preparations sold by illegal sources. In only two cases the content was the one reported on the labels.
[Show full text]
Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
[Show full text]
Influence of the Anabolic-Androgenic Steroid Nandrolone on Cannabinoid
Neuropharmacology 50 (2006) 788e806 www.elsevier.com/locate/neuropharm Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence Evelyne Ce´le´rier a, Therese Ahdepil b, Helena Wikander b, Fernando Berrendero a, Fred Nyberg b, Rafael Maldonado a,* a Laboratori of Neurofarmacologia, Facultat de Cieńcies de la Salut i de la Vida, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain b Department of Pharmaceutical Biosciences, University of Uppsala, Box 591 Biomedicum, S751 24 Uppsala, Sweden Received 8 April 2005; received in revised form 29 November 2005; accepted 29 November 2005 Abstract The identification of the possible factors that might enhance the risk of developing drug addiction and related motivational disorders is crucial to reduce the prevalence of these problems. Here, we examined in mice whether the exposure to the anabolic-androgenic steroid nandrolone would affect the pharmacological and motivational effects induced by D9-tetrahydrocannabinol (THC), the principal psychoactive component of Cannabis sativa. Mice received nandrolone using pre-exposure (during 14 days before THC treatment) or co-administration (1 h before each THC injection) procedures. Both nandrolone treatments did not modify the acute antinociceptive, hypothermic and hypolocomotor effects of THC or the development of tolerance after chronic THC administration. Nandrolone pre-exposure blocked THC- and food-induced condi- tioned place preference and increased the somatic manifestations of THC withdrawal precipitated by the CB1 cannabinoid antagonist rimona- bant (SR141617A). The aversive effects of THC were not changed by nandrolone. Furthermore, nandrolone pre-exposure attenuated the anxiolytic-like effects of a low dose of THC without altering the anxiogenic-like effects of a high dose in the lit/dark box, open field and elevated plus-maze.
[Show full text]
Chemical Muscle Enhancement (The BDR) by Author L
Chemical Muscle Enhancement (The BDR) By Author L. Rea TABLE OF CONTENTS 1. AAS INTRODUCTION ..PG’S 1-12 WARNING: READ FIRST OVER 20 YEARS AGO... WHY STEROIDS AND WHAT IS POSSIBLE? WHAT ARE STEROIDS? FEMALE HORMONE SYNTHESIS MALE HORMONE SYNTHESIS TESTOSTERONE... WHAT DOES IT DO? STEROIDS INCREASE PC SYNTHESIS STEROIDS EFFECT BLOOD VOLUME WHAT HAPPENS AFTER TESTOSTERONE MOLECULES LEAVE RECEPTORS? STEROIDS...GROWTH ON THE CELULAR LEVEL 2. DRUG REFERENCES AND DESCRIPTIONS..PG 12 ORAL ANABOLIC / ANDROGENIC STEROIDS..PG’S 13-30 INJECTABLE ANABOLIC / ANDROGENIC STEROIDS..PG’S 31-45 TESTOSTERONE AND ITS ESTERS..PG’S 45-61 NORTESTOSTERONE (NANDROLONE) AND ITS ESTER..PG’S 62-70 TRENBOLONE AND DERIVATIVES..PG’S 71-78 ESTROGEN CONTROL AND HPTA REGENERATION DRUGS..PG’S 79-94 DIURETICS..PG’S 95-102 THYROID HORMONES ..PG’S 103-116 NON-AAS GROWTH FACTORS AND RELATED SUBSTANCES..PG’S 117-141 OTHER SUBSTANCES..PG’S 142-152 3. REPORTED CYCLES AND EFFECTS.. (Introduction) PG’S 153-159 REPORTED CYCLES AND EFFECTS EXAMPLES (MALE)...PG’S 160-169 REPORTED CYCLES AND EFFECTS EXAMPLES (FEMALE)...PG’S 170-174 REPORTED ADVANCED CYCLES AND EFFECTS-BLITZ CYCLES..PG’S 175-200 (More Reported Cycles and Effects) 4. NUTRITION..PG’S..201-211 5. SUPPLEMENTAL CREATINE..PG’S 212-216 6. REFERENCES AND AVAILABLE LITERATURE..PG’S 217-223 All Rights Reserved CHEMICAL MUSCLE ENHANCEMENT (The Report) and BODYBUILDERS DESK REFERENCE COPYRIGHT ©2002 by AUTHOR L. REA No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopy, recording, or by any information storage and retrieval system, without the permission in writing of the author and publisher.
[Show full text]
A20-0767), As Follows:
05/05/20 03:02 pm HOUSE RESEARCH JD/RK H2711A8 1.1 .................... moves to amend H.F. No. 2711, the delete everything amendment 1.2 (A20-0767), as follows: 1.3 Page 21, delete section 1 1.4 Page 36, delete section 2 1.5 Page 40, delete section 3 and insert: 1.6 "Section 1. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read: 1.7 Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this subdivision. 1.8 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 1.9 following substances, including their analogs, isomers, esters, ethers, salts, and salts of 1.10 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 1.11 and salts is possible: 1.12 (1) acetylmethadol; 1.13 (2) allylprodine; 1.14 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 1.15 acetate); 1.16 (4) alphameprodine; 1.17 (5) alphamethadol; 1.18 (6) alpha-methylfentanyl benzethidine; 1.19 (7) betacetylmethadol; 1.20 (8) betameprodine; 1.21 (9) betamethadol; Section 1. 1 05/05/20 03:02 pm HOUSE RESEARCH JD/RK H2711A8 2.1 (10) betaprodine; 2.2 (11) clonitazene; 2.3 (12) dextromoramide; 2.4 (13) diampromide; 2.5 (14) diethyliambutene; 2.6 (15) difenoxin; 2.7 (16) dimenoxadol; 2.8 (17) dimepheptanol; 2.9 (18) dimethyliambutene; 2.10 (19) dioxaphetyl butyrate; 2.11 (20) dipipanone; 2.12 (21) ethylmethylthiambutene; 2.13 (22) etonitazene; 2.14 (23) etoxeridine; 2.15 (24) furethidine;
[Show full text]
Permanent Ban on Anabolic Androgenic Steroids From
Permanent Ban on Anabolic Androgenic Steroids to be introduced into the Greyhounds Australasia Rules Warning to trainers – Anabolic Androgenic Steroids (AAS) usage in greyhounds On 1 January 2016, Greyhounds Australasia will introduce Anabolic Androgenic Steroids to the list of Permanently Banned Prohibited Substances within GAR 79A (2) xx. as follows: “Anabolic androgenic steroids excluding those that are defined as an exempted substance pursuant to GAR 1.” The relevant exempted substance listed within GAR 1 is as follows: “Ethyloestrenol when administered orally to a greyhound bitch and where it has been prescribed by a veterinary surgeon for the sole purpose of regulating or preventing oestrus in that bitch.” Participants are advised that in accordance with GAR 79A they must never possess, acquire, attempt to acquire, administer or allow to be administered to any greyhound from birth until retirement, any anabolic androgenic steroid, excluding ethyloestrenol where it is appropriately prescribed for use as an oestrous suppressant in females. “Anabolic androgenic steroids” include those that are currently registered in Australia by the APVMA such as boldenone, ethyloestrenol, methandriol, nandrolone, stanozolol and testosterone. Others include but are not limited to 1- androstenediol; 1-androstenedione; bolandiol; bolasterone; boldione; calusterone; clostebol; danazol; dehydrochlormethyltestosterone; desoxymethyltestosterone; drostanolone; fluoxymesterone; formebolone; furazabol; gestrinone; 4-hydroxytestosterone; mestanolone; mesterolone;
[Show full text]
2096 Sex Hormones and Their Modulators
2096 Sex Hormones and their Modulators pertensive and potassium-sparing effects might be beneficial in timineralocorticoid effect of drospirenone has also been investi- women requiring treatment for both menopausal symptoms and gated and found to lower blood pressure in postmenopausal 4 hypertension (see also Menopausal Disorders, below). women with treated and untreated hypertension. OCH3 1. Karara AH, et al. Pharmacokinetics and pharmacodynamics of 1. Schürmann R, et al. Estradiol and drospirenone for climacteric drospirenone-estradiol combination hormone therapy product symptoms in postmenopausal women: a double-blind, rand- H3C coadministered with hydrochlorothiazide in hypertensive post- omized, placebo-controlled study of the safety and efficacy of menopausal women. J Clin Pharmacol 2007; 47: 1292–1302. three dose regimens. Climacteric 2004; 7: 189–96. 2. Preston RA, et al. Randomized, placebo-controlled trial of the 2. Whitehead M. Hormone replacement therapy with estradiol and H3C H effects of drospirenone-estradiol on blood pressure and potassi- drospirenone: an overview of the clinical data. J Br Menopause um balance in hypertensive postmenopausal women receiving Soc 2006; 12 (suppl 1): 4–7. hydrochlorothiazide. Menopause 2007; 14: 408–14. 3. Archer DF, et al. Long-term safety of drospirenone-estradiol for H H hormone therapy: a randomized, double-blind, multicenter trial. NSAIDs. Drospirenone has the potential to exacerbate the ef- Menopause 2005; 12: 716–27. O fects of other drugs, such as NSAIDs, that can increase serum 4. Mallareddy M, et al. Drospirenone, a new progestogen, for post- potassium. Licensed product information suggests that a clinical menopausal women with hypertension. Drugs Aging 2007; 24: effect is unlikely in practice, although the use of a number of 453–66.
[Show full text]
Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems. National Institute for Health and Welfare (THL), Research 30
Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic dissertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.
[Show full text]
NEWS 02 2020 ENG.Qxp Layout 1
Polymers and fluorescence Balance of power 360° drinking water analysis trilogy Fluorescence spectroscopy LCMS-8060NX: performance of industrial base polymers and robustness without Automatic, simultaneous and compromising sensitivity rapid analysis of pesticides and speed CONTENT APPLICATION »Plug und Play« disease screening solution? – The MALDI-8020 in screening for Sickle Cell Disease 4 Customized software solutions for any measurement – Macro programming for Shimadzu UV-Vis and FTIR 8 Ensuring steroid-free food supplements – Identification of steroids in pharmaceuticals and food supplements with LCMS-8045 11 MSn analysis of nonderivatized and Mtpp-derivatized peptides – Two recent studies applying LCMS-IT-TOF instruments 18 Polymers and fluorescence – Part 2: How much fluorescence does a polymer show during quality control? 26 PRODUCTS The balance of power – LCMS-8060NX balances enhanced performance and robustness 7 360° drinking water analysis: Episode 2 – Automatic, simul- taneous and rapid analysis of pesticides in drinking water by online SPE and UHPLC-MS/MS 14 Versatile testing tool for the automotive industry – Enrico Davoli with the PESI-MS system (research-use only [RUO] instrument) New HMV-G3 Series 17 No more headaches! A guide to choosing the perfect C18 column 22 Validated method for monoclonal antibody drugs – Assessment of the nSMOL methodology in Global solution through the validation of bevacizumab in human serum 24 global collaboration LATEST NEWS Global solution through global collaboration – Shimadzu Cancer diagnosis:
[Show full text]
2019 Prohibited List
THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
[Show full text]
Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems
Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic disSertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.
[Show full text]